Since 2013, BioAscent’s synthetic chemistry team has been providing high-quality services and participated in numerous hit-to-lead, lead generation, and optimisation campaigns. Our team is highly experienced and creative, with approximately 80% holding a PhD degree. BioAscent's synthetic chemistry capabilities include but are not limited to efficient and cost-saving route development and optimisation, building block synthesis, multi-step synthesis of complex molecules, asymmetric synthesis, parallel synthesis of ligand arrays and synthesis of reference molecules. Access to synthetic chemistry services at BioAscent is available as part of an integrated project or as a stand-alone service.
The synthetic chemistry team is supported by an in-house analytical team and a range of analytical techniques to ensure the quality of the output for both bespoke synthetic chemistry and library synthesis. These include 400MHz NMR with multi-nuclei probe and variable temperature capability, LCMS analysis including UPLC and SFC to provide access to chiral analysis and preparative enantiomer separations.
Problem solving is a key philosophy of the BioAscent chemistry team, with chemists regularly applying new and emerging technologies and creating innovative solutions to overcome synthetic challenges and to ensure customers’ requirements are satisfied.
"BioAscent has contributed at a key stage in our company’s evolution by synthesizing a panel of compounds for evaluation in our screening cascade. Every step in our interaction has been positive and effective, from the first discussion of our requirements to the delivery of samples for evaluation. The quality of product was very high, delivered on time, and supported by full documentation. What encourages me most to go back to BioAscent for further work when money allows and need arises, however, is their ability to propose and carry out improvements to the original laboratory synthesis method that we supplied. We’ve had a highly professional and cost-effective service.”
- Professor Colin Suckling, CSO, Rostra Therapeutics
To support our talented team we have a comprehensive range of equipment, including:
Optimization of Cyclophilin B-Targeted Tri-vector Inhibitors for Novel MASH Treatments. M-E. Kouridaki, J. Gillespie, J. Robinson, T. Mathie, L. Bain, D. McArthur, A. Morrison, D.B. Greenslade, M. Papadourakis, K. Maj, K. Cameron, D. Turner, S.P. Webster, M. A. Wear, D. Doughty-Shenton, A.N. Hulme, J. Michel. View paper.
Cell-active small molecule inhibitors validate the SNM1A DNA repair nuclease as a cancer target. M. Bielinski, L. R. Henderson, Y. Yosaatmadja, L. P. Swift, H. T. Baddock, M. J. Bowen, J. Brem, P. S. Jones, S. P. McElroy, A. Morrison, M. Speake, S. van Boeckel, E. van Doornmalen, J. van Groningen, H. van den Hurk, O. Gileadi, J. A. Newman, P. J. McHugh, C. J. Schofield. View paper.
Investigating the Structure-Activity Relationship of 1,2,4-Triazine G-Protein-Coupled Receptor 84 (GPR84) Antagonists. A. Mahindra, L. Jenkins, S. Marsango, M. Huggett, M. Huggett, L. Robinson, J. Gillespie, M. Rajamanickam, A. Morrison, S. McElroy, I. G. Tikhonova, G. Milligan, A. G. Jamieson. View paper.
The identification and characterisation of autophagy inhibitors from the published kinase inhibitor sets. M Zachari, J. Rainard, G. Pandarakalam, L. Robinson, J. Gillespie, M. Rajamanickam, V. Hamon, A. Morrison, I. Ganley, S. McElroy. View paper.
Identification of a novel class of benzofuran oxoacetic acid-derived ligands that selectively activate cellular EPAC; Cells; 8(11); 1425; 2019. E. Beck, E. Parnell, A. Cowley, A. Porter J. Gillespie, J. Robinson, L. Robinson, A. Pannifer, V. Hamon, P. Jones, A. Morrison, S. McElroy, M. Timmerman, H. Rutjes, P. Mahajan, J. Wiejak, U. Luchowska-Stańska, D. Morgan, G. Barker, H. Rehmann and S. Yarwood. View paper.
Synthesis and structure–activity relationships of N-(4-benzamidino)-oxazolidinones–potent and selective inhibitors of kallikrein-related peptidase 6; chemRxiv DOI: 10.26434/chemrxiv.9788276, 2019. E. De Vita, N. Smits, H. van den Hurk, E. Beck, J. Hewitt, G. Baillie, E. Russell, A. Pannifer, V. Hamon, A.Morrison, S. McElroy, P. Jones, N. Ignatenko, N. Gunkel and A. Miller. View paper.
Abstract LB-B17: Characterization of small molecule inhibitors of the Nrf2-Keap1 interaction using MicroScale Thermophoresis. Molecular Cancer Therapeutics 17 (1 Supplement), LB-B17-LB-B1. J. Rainard, A. Morrison, A. Pannifer, P. Jones, R. Mead, S. McElroy. View paper.
Comprehensive Medicinal Chemistry III, Chapter 1.18, 505-519; Eds. S. Chackalamannil, D. Rotella, S. Ward; Oxford: Elsevier; 2017. European Lead Factory; F. Giordanetto, P. Jones, A. Nelson, J. Benningshof, G. Muller, A. Pannifer, S. van Boeckel and D. Tzalis. View paper.
The importance of triaging in determining the quality of output from high-throughput screening. Future Medicinal Chemistry, 2015, Vol. 7, No. 14, Pages 1847-1852. P. Jones, S. McElroy, A. Morrison, A. Pannifer. View paper.
The Joint European Compound Library: boosting precompetitive research. Drug Discovery Today; 20, 181, 2015. J. Besnard, P. Jones, A. Hopkins and A. Pannifer. View paper.
